Pacira BioSciences, Inc. PCRX
Nasdaq · XNAS · stock · Pharmaceutical Preparations
Chart by TradingView
8/9
Piotroski F — financial health
3.08
Altman Z″ — distress risk · safe
—
Dividend payout · no dividend
Financials (annual, from 10-K)
| FY | Revenue | Net income | Gross profit | Free cash flow | Equity |
|---|---|---|---|---|---|
| 2025 | $726.4M | $7.0M | — | $136.7M | $693.1M |
| 2024 | $701.0M | -$99.6M | — | $178.8M | $778.3M |
| 2023 | $675.0M | $42.0M | — | $139.5M | $870.1M |
| 2022 | $666.8M | $15.9M | — | $115.2M | $775.0M |
| 2021 | $541.5M | $42.0M | — | $79.9M | $730.4M |
| 2020 | $429.6M | $145.5M | — | $39.2M | $619.7M |
Recent insider activity (Form 4)
| Insider | Role | Date | Action | Shares | Price |
|---|---|---|---|---|---|
| RIKER LAUREN | Senior Vice President, Finance | 2026-06-11 | Sell | 6,115 | $23.50 |
| CHRISTIE CHRISTOPHER | director | 2026-06-10 | Grant | 6,405 | — |
| Young Alethia | director | 2026-06-10 | Grant | 6,405 | — |
| YANG MICHAEL J. | director | 2026-06-10 | Grant | 6,405 | — |
| BIGAL MARCELO | director | 2026-06-10 | Grant | 6,405 | — |
| Froimson Mark | director | 2026-06-10 | Grant | 6,405 | — |
| Brege Laura | director | 2026-06-10 | Grant | 6,405 | — |
| Hirawat Samit | director | 2026-06-10 | Grant | 6,405 | — |
Why these scores methodology →
Piotroski F-score: 8/9
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″: 3.08 (safe)
- Working capital / assets 0.338
- Retained earnings / assets -0.158
- EBIT / assets 0.015
- Equity / liabilities 1.212
Source: SEC EDGAR filings · CIK 0001396814 · as of 2025-12-31. Figures are facts from filings plus Stocktoria's own computed scores — not investment advice.